|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess this, we studied the effects of HCV envelope protein E2 and T-tropic HIV envelope glycoprotein gp120 on hepatocytes and saw potent apoptosis.
|
14551890 |
2003 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used long-read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV infection to investigate the underlying viral population and evolutionary dynamics.
|
30602023 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The quasispecies of HCV showed various secondary structures of HVR1, but many sequences seemed to have common characteristics. beta sheet conformations around both the N-terminus and position 20 (numbered from the NH2 terminus of E2 envelope glycoprotein), and/or coil structures around the C-terminus of HVR1 could be identified.
|
12010507 |
2002 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, we compared non-proofreading (Taq) with proofreading (Advantage High Fidelity-2; HF-2) polymerases in the sensitivity, robustness, and HCV QS diversity and complexity in the second envelope glycoprotein gene hypervariable region 1 (E2-HVR1) on baseline specimens from 20 patients in the HALT-C trial and in a small cohort of 12 HCV/HIV co-infected patients.
|
15847697 |
2005 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
|
24990994 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicate that the antibody response to HCV E2 is affected by the genotype of the virus and that induction of a strong humoral immune response to HCV E2 may contribute to a decreased viral load.
|
11505439 |
2001 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this investigation, serum samples were analyzed for virological parameters, serum alanine aminotransferase (ALT) levels, and neutralizing antibody response against pseudotyped vesicular stomatitis virus (VSV) generated using chimeric envelope glycoprotein 1 (E1) or 2 (E2) of HCV.
|
11930327 |
2002 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, this effort has proven challenging because HCV evades neutralizing antibodies (NAbs) through molecular features of viral envelope glycoprotein E2, including hypervariable region 1 (HVR1) and N-linked glycans.
|
31040211 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inflammatory response of endothelial cells to hepatitis C virus recombinant envelope glycoprotein 2 protein exposure.
|
25317702 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we constructed genetic vaccines based on novel recombinant adeno‑associated viral (rAAV) vectors (AAV2/8 or AAV2/rh32.33) that express the envelope glycoprotein E2 from the HCV genotype 1b.
|
30569131 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.
|
18343477 |
2008 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus (HCV) envelope glycoprotein heterodimer, E1E2, plays an essential role in virus entry and assembly.
|
29755477 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus (HCV) envelope glycoprotein complex is composed of E1 and E2 subunits.
|
28179528 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular basis of benzimidazole inhibitors to hepatitis C virus envelope glycoprotein.
|
29745064 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human monoclonal antibody HCV1 recognizes a highly-conserved linear epitope of the HCV E2 envelope glycoprotein (amino acids 412-423) and neutralizes a broad range of HCV genotypes.
|
22952447 |
2012 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that the E2/NS1 antibody tested exhibits no neutralizing activity in chronic HCV infection but may serve as a serological indicator of active virus replication.
|
8621173 |
1996 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recombinant baculoviruses that produce a putative non-structural protein 1 (NS1) of hepatitis C virus (HCV), predicted to be the second envelope glycoprotein, were constructed.
|
7686870 |
1993 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
|
26278021 |
2016 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes.
|
17251563 |
2007 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We successfully recovered recombinant IBDVs expressing c-Myc and two different virus-neutralizing epitopes of human hepatitis C virus (HCV) envelope glycoprotein E in the VP5 region.
|
21106739 |
2011 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
|
10915068 |
2000 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HCV polyprotein contains a hypervariable region (HVR1) located at the N terminus of the second envelope glycoprotein E2.
|
11356980 |
2001 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses.
|
8083956 |
1994 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the interaction of apoE with viral envelope glycoprotein E2 and HCV virions by immunoprecipitation.
|
26404951 |
2016 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the roles of N-glycans of hepatitis C virus (HCV) E2 envelope glycoprotein in specific cellular immune responses remain elusive.
|
17055129 |
2007 |